Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
PTIE's Cash-to-Debt is ranked higher than
95% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. PTIE: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
PTIE' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
PTIE's Interest Coverage is ranked higher than
94% of the 484 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. PTIE: No Debt )
Ranked among companies with meaningful Interest Coverage only.
PTIE' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 4
Altman Z-Score: 11.77
Beneish M-Score: 12.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -63.69
PTIE's ROE % is ranked lower than
68% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. PTIE: -63.69 )
Ranked among companies with meaningful ROE % only.
PTIE' s ROE % Range Over the Past 10 Years
Min: -63.69  Med: -9.37 Max: 102.69
Current: -63.69
-63.69
102.69
ROA % -58.34
PTIE's ROA % is ranked lower than
71% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. PTIE: -58.34 )
Ranked among companies with meaningful ROA % only.
PTIE' s ROA % Range Over the Past 10 Years
Min: -58.34  Med: -3.53 Max: 58.98
Current: -58.34
-58.34
58.98
ROC (Joel Greenblatt) % -6918.13
PTIE's ROC (Joel Greenblatt) % is ranked lower than
85% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. PTIE: -6918.13 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PTIE' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -38255.38  Med: -3417.21 Max: 731.79
Current: -6918.13
-38255.38
731.79
3-Year Revenue Growth Rate -100.00
PTIE's 3-Year Revenue Growth Rate is ranked lower than
94% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. PTIE: -100.00 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PTIE' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -100 Max: 132.2
Current: -100
0
132.2
GuruFocus has detected 3 Warning Signs with Pain Therapeutics Inc $PTIE.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PTIE's 10-Y Financials

Financials (Next Earnings Date: 2017-03-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PTIE Guru Trades in Q1 2016

Charles Brandes 37,719 sh (+107.92%)
Jim Simons 726,987 sh (+8.06%)
Mario Gabelli 65,000 sh (unchged)
First Eagle Investment 5,684,510 sh (unchged)
» More
Q2 2016

PTIE Guru Trades in Q2 2016

Charles Brandes 78,758 sh (+108.80%)
First Eagle Investment 6,602,658 sh (+16.15%)
Jim Simons 799,787 sh (+10.01%)
Mario Gabelli 65,000 sh (unchged)
» More
Q3 2016

PTIE Guru Trades in Q3 2016

Jim Simons 910,187 sh (+13.80%)
First Eagle Investment 6,602,658 sh (unchged)
Mario Gabelli 65,000 sh (unchged)
Charles Brandes 53,200 sh (-32.45%)
» More
Q4 2016

PTIE Guru Trades in Q4 2016

Mario Gabelli 110,000 sh (+69.23%)
First Eagle Investment 6,602,658 sh (unchged)
Charles Brandes Sold Out
Jim Simons 836,187 sh (-8.13%)
» More
» Details

Insider Trades

Latest Guru Trades with PTIE

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:PKTX, AMEX:CANF, NAS:ONCS, NAS:ICCC, NAS:GALE, NAS:CLRB, NAS:AVIR, NAS:VICL, NAS:CYAN, NAS:ABIO, NAS:ANTH, NAS:VTGN, AMEX:BPMX, OTCPK:PRTX, OTCPK:RGIN, NAS:RPRX, AMEX:MSTX, AMEX:OGEN, OTCPK:EMIS, OTCPK:OBMP » details
Traded in other countries:PX9.Germany,
Pain Therapeutics Inc is a biopharmaceutical company that develops novel drugs. The Company has four drug candidates in clinical programs, including Remoxy, Oxytrex, PTI-202 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma.

Pain Therapeutics Inc a Delaware corporation was incorporated in May 1998. The Company is a biopharmaceutical company that develops novel drugs. The Company has four drug candidates in clinical programs, including REMOXY, PTI-202, PTI-721 and a novel radio-labeled monoclonal antibody to treat metastatic melanoma. Its drug candidate is called REMOXY. REMOXY is a painkiller with a formulation designed to reduce potential risks of unintended use. REMOXY is a novel controlled-release oral capsule form of oxycodone in a viscous liquid formulation matrix that includes novel excipients. The Company owns all commercial rights to its pipeline of drug candidates in oncology and hematology. It relies on a limited number of third-party manufacturers to formulate, manufacture, fill, label, ship or store all of its drug candidates. The company's strategies include Focus on Clinical Development Stage Products. It currently retains commercialization rights to all of its technology and drug candidates in all markets and indications, except for REMOXY and certain other abuse-resistant drugs. The Company has an exclusive Development and License Agreement, or the Durect Agreement, with Durect Corporation, or Durect, to use a patented technology that forms the basis for certain drug candidates, including REMOXY. Companies that currently sell generic or proprietary opioid formulations include, but are not limited to, Roxane Laboratories, Purdue Pharma, Pfizer, Abbott Laboratories, Endo Pharmaceuticals, Teva Pharmaceuticals, Elkins-Sinn, Watson Laboratories, Ortho-McNeil Pharmaceutical and Forest Pharmaceuticals. The Company is subject to governmental regulations.

Ratios

vs
industry
vs
history
PB Ratio 1.40
PTIE's PB Ratio is ranked higher than
85% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. PTIE: 1.40 )
Ranked among companies with meaningful PB Ratio only.
PTIE' s PB Ratio Range Over the Past 10 Years
Min: 0.58  Med: 3.83 Max: 15.24
Current: 1.4
0.58
15.24
EV-to-EBIT -0.51
PTIE's EV-to-EBIT is ranked lower than
99.99% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. PTIE: -0.51 )
Ranked among companies with meaningful EV-to-EBIT only.
PTIE' s EV-to-EBIT Range Over the Past 10 Years
Min: -409  Med: -0.7 Max: 1338.1
Current: -0.51
-409
1338.1
EV-to-EBITDA -0.51
PTIE's EV-to-EBITDA is ranked lower than
99.99% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. PTIE: -0.51 )
Ranked among companies with meaningful EV-to-EBITDA only.
PTIE' s EV-to-EBITDA Range Over the Past 10 Years
Min: -82.3  Med: 0.65 Max: 86.5
Current: -0.51
-82.3
86.5
Shiller PE Ratio 28.63
PTIE's Shiller PE Ratio is ranked lower than
55% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 47.42 vs. PTIE: 28.63 )
Ranked among companies with meaningful Shiller PE Ratio only.
PTIE' s Shiller PE Ratio Range Over the Past 10 Years
Min: 13.77  Med: 59.13 Max: 451
Current: 28.63
13.77
451
Current Ratio 28.68
PTIE's Current Ratio is ranked higher than
78% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. PTIE: 28.68 )
Ranked among companies with meaningful Current Ratio only.
PTIE' s Current Ratio Range Over the Past 10 Years
Min: 5.65  Med: 12.6 Max: 48.03
Current: 28.68
5.65
48.03
Quick Ratio 28.68
PTIE's Quick Ratio is ranked higher than
78% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. PTIE: 28.68 )
Ranked among companies with meaningful Quick Ratio only.
PTIE' s Quick Ratio Range Over the Past 10 Years
Min: 5.65  Med: 12.6 Max: 48.03
Current: 28.68
5.65
48.03

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.10
PTIE's 3-Year Average Share Buyback Ratio is ranked higher than
93% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. PTIE: -0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PTIE' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -101.1  Med: -2 Max: 1.5
Current: -0.1
-101.1
1.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.43
PTIE's Price-to-Net-Cash is ranked higher than
93% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: 5.89 vs. PTIE: 1.43 )
Ranked among companies with meaningful Price-to-Net-Cash only.
PTIE' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.38  Med: 3.92 Max: 30.22
Current: 1.43
1.38
30.22
Price-to-Net-Current-Asset-Value 1.43
PTIE's Price-to-Net-Current-Asset-Value is ranked higher than
92% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. PTIE: 1.43 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
PTIE' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.35  Med: 3.88 Max: 9.68
Current: 1.43
1.35
9.68
Price-to-Tangible-Book 1.40
PTIE's Price-to-Tangible-Book is ranked higher than
89% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. PTIE: 1.40 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
PTIE' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.29  Med: 3.75 Max: 9.34
Current: 1.4
1.29
9.34
Earnings Yield (Greenblatt) % -196.10
PTIE's Earnings Yield (Greenblatt) % is ranked lower than
97% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. PTIE: -196.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PTIE' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 17.4 Max: 1032.2
Current: -196.1
0.1
1032.2

More Statistics

EPS (TTM) $ -0.34
Beta1.96
Short Percentage of Float3.12%
52-Week Range $0.51 - 3.00
Shares Outstanding (Mil)46.14

Analyst Estimate

Dec17 Dec18
Revenue (Mil $)
EPS ($) -0.40 -0.50
EPS without NRI ($) -0.40 -0.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PTIE

Headlines

Articles On GuruFocus.com
Wednesday Pre-Market Insights: GEVO, WPZ, HDP, PTIE May 13 2015 
Eveillard's First Eagle Increases 2 Positions Sep 11 2014 
Morning Coffee: Real-Time Picks May 14 2014 
Pain Therapeutics Reports Operating Results (10-K) Feb 03 2011 
Pain Therapeutics Reports Operating Results (10-Q) Oct 29 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 50,000 Shares Oct 04 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 28,597 Shares Sep 08 2010 
Pain Therapeutics (ptie) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 21,403 Shares Sep 02 2010 
Pain Therapeutics (PTIE) CEO & Chairman of the Board, 10% Owner Remi Barbier sells 22,391 Shares Aug 04 2010 
Pain Therapeutics Reports Operating Results (10-Q) Jul 29 2010 

More From Other Websites
Here’s What The Latest Pain Therapeutics, Inc. (PTIE) Update Means Feb 21 2017
Pain Therapeutics reports 4Q loss Feb 17 2017
Pain Therapeutics reports 4Q loss Feb 17 2017
PAIN THERAPEUTICS INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 17 2017
Pain Therapeutics Reports 2016 Financial Results Feb 17 2017
Pain Therapeutics to Discuss REMOXY® ER with FDA Dec 20 2016
Pain Therapeutics, Inc. (PTIE): How Does It Compare Against Its Peers? Dec 16 2016
Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Pain... Dec 11 2016
PAIN THERAPEUTICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events Dec 08 2016
PAIN THERAPEUTICS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued... Nov 18 2016
Durect (DRRX) Exited Third Quarter with Strong Balance Sheet Nov 01 2016
PAIN THERAPEUTICS INC Financials Oct 29 2016
PAIN THERAPEUTICS INC Files SEC form 10-Q, Quarterly Report Oct 26 2016
Pain Therapeutics Reports Q3 2016 Financial Results Oct 20 2016
PAIN THERAPEUTICS INC Files SEC form 8-K, Results of Operations and Financial Condition Oct 20 2016
Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Pain... Oct 11 2016
Pain Therapeutics (PTIE) Enters Oversold Territory Sep 29 2016
Pain Therapeutics (PTIE) Down on CRL for Chronic Pain Drug Sep 28 2016
Durect Corp. (DRRX) Stock Tumbles on FDA Opioid Analgesic Drug Rejection Sep 26 2016
5 Big-Volume Stocks You Should Stay Away From -- Plus 2 to Buy Sep 26 2016
GW Pharmaceuticals (GWPH), Sally Beauty Holdings Inc. (SBH) & More: Why These Stocks Are Making... Sep 26 2016
For Pain Therapeutics CEO, 3 FDA Rejections Are Worth $23 Million Sep 26 2016
Is Pain Therapeutics an Incredible Momentum Stock? 3 Reasons Why PTIE Will Be Tough to Beat Sep 26 2016
Complete Response Letter for REMOXY® Sep 26 2016
DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER... Sep 26 2016
PAIN THERAPEUTICS INC Files SEC form 8-K, Other Events Sep 26 2016
Pain Therapeutics Announces Advisory Committee Meeting for REMOXY® Is Not Needed Jul 01 2016
Pain Therapeutics Announces FDA Advisory Committee Meeting for REMOXY® May 19 2016
Pain Therapeutics Reports Q1 2016 Financial Results May 05 2016
FDA Accepts REMOXY NDA for Review, Sets PDUFA Date of September 25, 2016 Apr 12 2016
Pain Therapeutics Resubmits REMOXY New Drug Application to the U.S. Food and Drug Administration Mar 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)